These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 24394747)

  • 1. The impact of buprenorphine transdermal delivery system on activities of daily living among patients with chronic low back pain: an application of the international classification of functioning, disability and health.
    Miller K; Yarlas A; Wen W; Dain B; Lynch SY; Ripa SR; Pergolizzi JV; Raffa R
    Clin J Pain; 2014 Dec; 30(12):1015-22. PubMed ID: 24394747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, placebo-controlled study of the impact of the 7-day buprenorphine transdermal system on health-related quality of life in opioid-naïve patients with moderate-to-severe chronic low back pain.
    Yarlas A; Miller K; Wen W; Dain B; Lynch SY; Pergolizzi JV; Raffa RB; Ripa SR
    J Pain; 2013 Jan; 14(1):14-23. PubMed ID: 23200931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study.
    Steiner DJ; Sitar S; Wen W; Sawyerr G; Munera C; Ripa SR; Landau C
    J Pain Symptom Manage; 2011 Dec; 42(6):903-17. PubMed ID: 21945130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buprenorphine Transdermal System Improves Sleep Quality and Reduces Sleep Disturbance in Patients with Moderate-to-Severe Chronic Low Back Pain: Results from Two Randomized Controlled Trials.
    Yarlas A; Miller K; Wen W; Lynch SY; Ripa SR; Pergolizzi JV; Raffa RB
    Pain Pract; 2016 Mar; 16(3):345-58. PubMed ID: 25599968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Buprenorphine transdermal system compared with placebo reduces interference in functioning for chronic low back pain.
    Yarlas A; Miller K; Wen W; Lynch SY; Munera C; Pergolizzi JV; Raffa R; Ripa SR
    Postgrad Med; 2015 Jan; 127(1):38-45. PubMed ID: 25526229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Buprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back pain.
    Miller K; Yarlas A; Wen W; Dain B; Lynch SY; Brennan MJ; Ripa SR
    Expert Opin Pharmacother; 2013 Feb; 14(3):269-77. PubMed ID: 23374027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study.
    Steiner D; Munera C; Hale M; Ripa S; Landau C
    J Pain; 2011 Nov; 12(11):1163-73. PubMed ID: 21807566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.
    Landau CJ; Carr WD; Razzetti AJ; Sessler NE; Munera C; Ripa SR
    Clin Ther; 2007 Oct; 29(10):2179-93. PubMed ID: 18042474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Subgroup Analysis Found no Diminished Response to Buprenorphine Transdermal System Treatment for Chronic Low Back Pain Patients Classified with Depression.
    Yarlas A; Miller K; Wen W; Lynch SY; Munera C; Dain B; Pergolizzi JV; Raffa R; Ripa SR
    Pain Pract; 2016 Apr; 16(4):473-85. PubMed ID: 25865734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective analysis of 4 years of clinical experience with transdermal buprenorphine (Transtec) in post-traumatic pain.
    Correa-Illanes G; Roa RG; B Piñeros JL; Ferrer FT; Adriasola VR
    Pain Manag; 2014 May; 4(3):181-90. PubMed ID: 24835268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buprenorphine transdermal system for opioid therapy in patients with chronic low back pain.
    Gordon A; Rashiq S; Moulin DE; Clark AJ; Beaulieu AD; Eisenhoffer J; Piraino PS; Quigley P; Harsanyi Z; Darke AC
    Pain Res Manag; 2010; 15(3):169-78. PubMed ID: 20577660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and Safety of Transdermal Buprenorphine Versus Sustained-release Tramadol in Patients With Moderate to Severe Musculoskeletal Pain: An 8-Week, Randomized, Double-Blind, Double-Dummy, Multicenter, Active-controlled, Noninferiority Study.
    Leng X; Li Z; Lv H; Zheng Y; Liu Y; Dai K; Yao C; Yan X; Zeng X
    Clin J Pain; 2015 Jul; 31(7):612-20. PubMed ID: 25503600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of buccal buprenorphine in opioid-naive patients with moderate to severe chronic low back pain.
    Rauck RL; Potts J; Xiang Q; Tzanis E; Finn A
    Postgrad Med; 2016 Jan; 128(1):1-11. PubMed ID: 26634956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
    Sorge J; Sittl R
    Clin Ther; 2004 Nov; 26(11):1808-20. PubMed ID: 15639693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buprenorphine transdermal system utilization.
    Wallace L; Kadakia A
    Postgrad Med; 2017 Jan; 129(1):81-86. PubMed ID: 27901359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-weekly transdermal buprenorphine application results in sustained and consistent steady-state plasma levels.
    Kapil RP; Cipriano A; Friedman K; Michels G; Shet MS; Colucci SV; Apseloff G; Kitzmiller J; Harris SC
    J Pain Symptom Manage; 2013 Jul; 46(1):65-75. PubMed ID: 23026548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of single-entity, once-daily hydrocodone tablets in patients with uncontrolled moderate to severe chronic low back pain.
    Wen W; Sitar S; Lynch SY; He E; Ripa SR
    Expert Opin Pharmacother; 2015; 16(11):1593-606. PubMed ID: 26111544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Buprenorphine transdermal system in adults with chronic low back pain: a randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phase.
    Gordon A; Callaghan D; Spink D; Cloutier C; Dzongowski P; O'Mahony W; Sinclair D; Rashiq S; Buckley N; Cohen G; Kim J; Boulanger A; Piraino PS; Eisenhoffer J; Harsanyi Z; Darke AC; Michalko KJ
    Clin Ther; 2010 May; 32(5):844-60. PubMed ID: 20685494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
    Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
    Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application site adverse events associated with the buprenorphine transdermal system: a pooled analysis.
    Wen W; Lynch SY; Munera C; Swanton R; Ripa SR; Maibach H
    Expert Opin Drug Saf; 2013 May; 12(3):309-19. PubMed ID: 23506252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.